Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

• Status: Not yet recruiting
• Trial end date: 2025-02-10
• Target enrollment: 0
• Participant gender: Female

Summary

To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sichuan Cancer Hospital and Research Institute
• Treatments: Aprepitant

Criteria

Inclusion Criteria:

1. Age 20-75 years old;

2. ECOG PS：0～2;

3. She was diagnosed as gynecological malignant tumor and was to receive TC chemotherapy;

4. Carboplatin AUC 5～6mg/ml/min；

5. Basically normal organ function (normal bilirubin level circumference, normal range of creatinine, ALT< 2 times the upper limit of normal, AST< 2 times the upper normal value)

Exclusion Criteria:

1. Patients with previous history of chemotherapy, radiotherapy or targeted therapy;

2. Malignant tumors with brain metastases;

3. History of gastrointestinal malignancy;

4. History of brain tumor;

5. Previous gastrointestinal surgery history, such as segmental resection, (partial) gastrectomy, except intestinal polyp resection and appendectomy;

6. (incomplete) intestinal obstruction;

7. Vestibular dysfunction;

8. Massive abdominal accumulation liquid (except for those who have undergone puncture drainage);

9. Opioid concomitant drug users;

10. Diabetic.